ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2346

Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis
Abstract Number: 0390

Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis
Abstract Number: 2093

Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial
Abstract Number: 0736

Treatment of IgG4-Related Disease (IgG4-RD) with Elotuzumab, an Inhibitor of SLAM-F7: Report of a Phase 2 Clinical Trial
Abstract Number: 2491

Treatment Outcomes of Eosinophilic Granulomatosis with Polyangiitis (EGPA):A Retrospective Analysis of US Health Insurance Claims Data
Abstract Number: 1119

Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis
Abstract Number: 0345

Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh’s Myositis Registry
Abstract Number: 0663

Treatment Patterns and the Prevalence of Kidney Biopsy-Confirmed LN in Patients with SLE and Proteinuria: A Multicenter Cohort Study
Abstract Number: 1454

Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US
Abstract Number: 1691

Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease
Abstract Number: 2231

Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort
Abstract Number: 1845

Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis
Abstract Number: 1523

Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020
Abstract Number: 0998

Trends and Disparities in Cardiovascular Deaths in Systemic Lupus Erythematosus: A Population-Based Retrospective Study in the United States from 1999 to 2021
Abstract Number: 2621

Trends in Disease Activity in Rheumatoid Arthritis over 2009-2023 Utilizing DAS28-CRP Inferred from Electronic Health Records

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].